Suma Krishnan - Apr 17, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Suma Krishnan
Stock symbol
KRYS
Transactions as of
Apr 17, 2023
Transactions value $
-$4,382,424
Form type
4
Date filed
4/18/2023, 04:08 PM
Previous filing
Feb 28, 2023
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale -$89.8K -1.05K -0.06% $85.55 1.67M Apr 17, 2023 Direct F1, F2
transaction KRYS Common Stock Sale -$373K -4.3K -0.26% $86.80 1.67M Apr 17, 2023 Direct F1, F3
transaction KRYS Common Stock Sale -$824K -9.43K -0.56% $87.41 1.66M Apr 17, 2023 Direct F1, F4
transaction KRYS Common Stock Sale -$860K -9.72K -0.59% $88.41 1.65M Apr 17, 2023 Direct F1, F5
transaction KRYS Common Stock Sale -$44.6K -500 -0.03% $89.12 1.65M Apr 17, 2023 Direct F1, F6
transaction KRYS Common Stock Sale -$89.8K -1.05K -0.06% $85.55 1.74M Apr 17, 2023 By Spouse F2, F7, F8, F9
transaction KRYS Common Stock Sale -$373K -4.3K -0.25% $86.80 1.73M Apr 17, 2023 By Spouse F3, F7, F8, F9
transaction KRYS Common Stock Sale -$824K -9.43K -0.54% $87.41 1.72M Apr 17, 2023 By Spouse F4, F7, F8, F9
transaction KRYS Common Stock Sale -$860K -9.72K -0.56% $88.41 1.71M Apr 17, 2023 By Spouse F5, F7, F8, F9
transaction KRYS Common Stock Sale -$44.6K -500 -0.03% $89.12 1.71M Apr 17, 2023 By Spouse F6, F7, F8, F9
holding KRYS Common Stock 90K Apr 17, 2023 By SMK Trust
holding KRYS Common Stock 50K Apr 17, 2023 By Krishnan Family Trust F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.
F2 The transaction was executed in multiple trades ranging from $85.0500 to $86.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $86.0500 to $87.0450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $87.0500 to $88.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The transaction was executed in multiple trades ranging from $88.0500 to $89.0100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The transaction was executed in multiple trades ranging from $89.0650 to $89.2300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.
F8 These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.
F9 Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
F10 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.